Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review
-
By
-
May 1, 2026
-
1
Bone marrow hemodilution can lead to false negative results in measurable residual disease assessments in multiple myeloma.
-
2
Next Generation Flow Cytometry is preferred for MRD identification due to its cost-effectiveness and ability to evaluate hemodilution.
-
3
Hemodilution significantly impacts MRD evaluation in multiple myeloma due to the heterogeneous distribution of plasma cells.
-
4
Mast cells, nucleated red blood cells, and B cell progenitors are key cellular subpopulations used to assess hemodilution.
-
5
A combined evaluation of multiple cellular parameters is recommended for more reliable hemodilution assessments in multiple myeloma.